

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on 14 Nov. 2008

TOWNSEND and TOWNSEND and CREW LLP

By: Mulinder Dogra

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE –
EXAMINING GROUP 1643

PATENT

Attorney Docket No.: 015280-317100US

Client Ref. No.: E-059-1997/0-US-07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FitzGerald et al.

Application No.: 09/381,497

Filed: February 17, 2000

For: RECOMBINANT ANTIBODIES
AND IMMUNOCONJUGATES
TARGETED TO CD-22 BEARING
CELLS AND TUMORS

Customer No.: 45115

Confirmation No. 4036

Examiner: Parithosh K. Tungaturthi

Technology Center/Art Unit: 1643

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1643

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed August 14, 2008 on the above-referenced application, please enter the following remarks.

The current **Claims** are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.